IL-2 treatment restores the ability of XLT and WAS NK cells to form conjugates with K562 target cells
. | Binding time . | . | . | . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| . | Medium alone . | . | . | IL-2 . | . | . | |||||
| Sample . | 0 min . | 15 min . | 30 min . | 0 min . | 15 min . | 30 min . | |||||
| Healthy donors | |||||||||||
| Mean ± SD* | 2.1 ± 0.5 | 15 ± 1.9 | 16.5 ± 0.4 | 2.4 ± 0.3 | 23.0 ± 1.3 | 25.1 ± 2.0 | |||||
| Patients with XLT | |||||||||||
| W2 | 1.5 | 7.8 | 7.5 | 1.6 | 20.0 | 17.6 | |||||
| W3 | 1.6 | 7.5 | 7.0 | 2.1 | 21.0 | 20.0 | |||||
| W18 | 1.5 | 8.1 | 5.5 | 2.5 | 19.2 | 18.0 | |||||
| W19 | 1.7 | 7.2 | 8.0 | 1.9 | 18.0 | 23.0 | |||||
| Mean ± SD | 1.6 ± 0.1 | 7.6 ± 0.4 | 7.0 ± 1.0 | 2.0 ± 0.4 | 19.5 ± 1.3 | 19.6 ± 2.4 | |||||
| Patients with WAS | |||||||||||
| W4 | 1.0 | 7.2 | 8.6 | 1.4 | 23.0 | 22.0 | |||||
| W15 | 1.1 | 6.1 | 7.4 | 1.3 | 20.0 | 21.0 | |||||
| W22 | 0.9 | 8.5 | 9.9 | 0.4 | 29.0 | 28.6 | |||||
| Mean ± SD | 1.0 ± 0.1 | 7.2 ± 1.2 | 8.6 ± 1.2 | 1.0 ± 0.5 | 24.0 ± 4.6 | 23.9 ± 4.1 | |||||
. | Binding time . | . | . | . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| . | Medium alone . | . | . | IL-2 . | . | . | |||||
| Sample . | 0 min . | 15 min . | 30 min . | 0 min . | 15 min . | 30 min . | |||||
| Healthy donors | |||||||||||
| Mean ± SD* | 2.1 ± 0.5 | 15 ± 1.9 | 16.5 ± 0.4 | 2.4 ± 0.3 | 23.0 ± 1.3 | 25.1 ± 2.0 | |||||
| Patients with XLT | |||||||||||
| W2 | 1.5 | 7.8 | 7.5 | 1.6 | 20.0 | 17.6 | |||||
| W3 | 1.6 | 7.5 | 7.0 | 2.1 | 21.0 | 20.0 | |||||
| W18 | 1.5 | 8.1 | 5.5 | 2.5 | 19.2 | 18.0 | |||||
| W19 | 1.7 | 7.2 | 8.0 | 1.9 | 18.0 | 23.0 | |||||
| Mean ± SD | 1.6 ± 0.1 | 7.6 ± 0.4 | 7.0 ± 1.0 | 2.0 ± 0.4 | 19.5 ± 1.3 | 19.6 ± 2.4 | |||||
| Patients with WAS | |||||||||||
| W4 | 1.0 | 7.2 | 8.6 | 1.4 | 23.0 | 22.0 | |||||
| W15 | 1.1 | 6.1 | 7.4 | 1.3 | 20.0 | 21.0 | |||||
| W22 | 0.9 | 8.5 | 9.9 | 0.4 | 29.0 | 28.6 | |||||
| Mean ± SD | 1.0 ± 0.1 | 7.2 ± 1.2 | 8.6 ± 1.2 | 1.0 ± 0.5 | 24.0 ± 4.6 | 23.9 ± 4.1 | |||||
NK cells from healthy donors and from patients with XLT or WAS, treated or not treated with human recombinant IL-2 (250 IU/mL) for 48 hours, were loaded with calceine am and then allowed to bind to K562 target cells (E/T ratio, 5:1) for the indicated times at 37°C. After incubation, cells were gently resuspended and fixed, and the conjugate percentages were evaluated on green fluorescence-positive cells by analyzing forward scatter compared with green fluorescence.
Statistical analyses performed using the Student t test comparing the mean percentages of NK cell-target cell conjugates in patients with XLT and WAS with those in control donors demonstrated significantly inhibited conjugate formation in XLT and WAS (P < .005 at 15 and 30 minutes) and IL-2-mediated correction of this defect in both (P > .05).
Data are expressed as percentage conjugates obtained in 4 healthy donors.